Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker(University of Arkansas for Medical Sciences), Konstantinos Mavrommatis, Christopher P. Wardell(University of Arkansas for Medical Sciences), Cody Ashby(University of Arkansas for Medical Sciences), Michael Bauer(University of Arkansas for Medical Sciences), Faith E. Davies(University of Arkansas for Medical Sciences), Adam Rosenthal(Cancer Research And Biostatistics), Hongwei Wang(Cancer Research And Biostatistics), Pingping Qu(Cancer Research And Biostatistics), Antje Hoering(Cancer Research And Biostatistics), Mehmet Samur(Harvard University), Fadi Towfic, María Ortiz, Erin Flynt, Zhinuan Yu, Zhihong Yang, Dan Rozelle(Rancho BioSciences (United States)), John C. Obenauer(Rancho BioSciences (United States)), Matthew Trotter, Daniel Auclair(Multiple Myeloma Research Foundation), Jonathan J. Keats(Translational Genomics Research Institute), Niccolò Bolli(University of Milan), Mariateresa Fulciniti(Harvard University), Raphaël Szalat(Harvard University), Philippe Moreau(Nantes Université), Brian G.M. Durie(Cedars-Sinai Medical Center), A. Keith Stewart(Mayo Clinic in Arizona), Hartmut Goldschmidt(Heidelberg University), Marc S. Raab(German Cancer Research Center), Hermann Einsele(University of Würzburg), Pieter Sonneveld(Erasmus MC Cancer Institute), Jesús F. San Miguel(Navarre Institute of Health Research), Sagar Lonial(Emory University), Graham Jackson(Newcastle University), Kenneth C. Anderson(Harvard University), Hervé Avet‐Loiseau(Inserm), Nikhil Munshi(Harvard University), Anjan Thakurta, Gareth J. Morgan(University of Arkansas for Medical Sciences)
Cited by 490Open Access
Abstract
rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.